FDA pathway for bespoke medicines & UK baby after womb transplant - News (Feb 24, 2026)

Let’s start with healthcare policy, because Washington just put a marker down on how future ultra-rare disease treatments might get reviewed. On February 23rd, the Trump administration released detailed FDA guidance describing a “plausible mechanism pathway” for so-called bespoke medicines—therapies designed for a single patient, or a tiny handful of patients, with extremely rare genetic mutations. The idea is simple in concept and complicated in practice: when you can’t run a traditional clinical program because the patient population is too small, the FDA may consider evidence built around a credible biological mechanism—especially relevant to gene-editing and other genetic approaches. Commissioner Marty Makary and biologics chief Vinay Prasad previewed this in a medical journal late last year, and this new document is the first operational step. Supporters see it as a way to turn isolated “one-off” success stories into a repeatable pathway. But the guidance also draws boundaries on what qualifies, and a big open question is how broad this will become once submissions start flowing—which the FDA expects could be a lot.

Now to the medical milestone that grabbed attention in the UK: a baby boy named Hugo is the first child in the country born after his mother received a womb transplant from a deceased donor. His mother, Grace Bell from Kent, was born with MRKH syndrome—meaning she didn’t have a viable womb, though her ovaries function normally. She underwent a roughly 10-hour transplant surgery in Oxford in June 2024, then pursued IVF and embryo transfer through a London fertility clinic. Hugo was delivered by C-section at Queen Charlotte’s and Chelsea Hospital just before Christmas 2025, and he’s now about 10 weeks old. Doctors and the family highlighted an important detail: the baby has no genetic link to the donor—the transplanted womb is the environment for pregnancy, not the source of DNA. The case is part of a UK trial of deceased-donor womb transplants, and the team involved also noted a practical medical reality: the womb may later be removed so Bell won’t need lifelong anti-rejection medication. For patients told they cannot carry a pregnancy, this is a new kind of hope—paired with careful, long-term clinical follow-up.

Staying in genetics, researchers at the University of Pennsylvania and Rice University reported a precision upgrade to a popular form of gene editing known as base editing—work that could make future treatments safer. Base editors don’t cut DNA like classic CRISPR approaches; they’re designed to swap one “letter” of DNA for another, which matters because many diseases come down to single-letter errors. The problem has been “bystander” edits—unintended changes to nearby DNA, even if you hit the right general neighborhood. In a new paper in Molecular Therapy, the team focused on edits involving cytosine and thymine, and tackled a tricky pattern: clusters of cytosines that can tempt the editor to alter more than you want. Their fix was partly mechanical—shortening and stiffening the molecular “linker” so the editing enzyme can’t reach as far—and partly chemical, by weakening certain DNA interactions. In human-cell tests, the best redesigned editor reduced unintended bystander edits by more than 80%, while keeping strong on-target activity. At cystic-fibrosis-relevant sites, they reported bystander rates dropping from as high as 50–60% to below 1%, and they restored function in engineered cell models. This is still preclinical, but it’s the kind of incremental safety improvement that makes real-world therapies more plausible—especially for diseases with many mutation-specific versions, like cystic fibrosis.

Switching to consumer tech: Apple and Google say testing is now underway for end-to-end encrypted RCS messaging between Android phones and iPhones. RCS—Rich Communication Services—is basically the modern replacement for SMS and has already brought iPhone-to-Android upgrades like read receipts, typing indicators, and better-quality media. The missing piece has been strong encryption across platforms. In this beta phase, iPhone users need iOS 26.4 beta 2 and a supported carrier, and the setting for “End-to-End Encryption (Beta)” should be enabled under Messages and RCS options. Android users need the latest Google Messages beta. Both companies are warning that, as with most betas, there may be delivery hiccups. If you’re watching for the tell: on iPhone, RCS chats still show as green bubbles, but the header will indicate RCS with a lock icon and an “Encrypted” label. The bigger point here is momentum—this is a concrete step toward private, default encryption for the messages people actually send every day, regardless of which phone they picked.

Meanwhile, China’s humanoid-robot industry is making a noticeable leap from novelty to something that looks—at least on stage—more like a product category. During the state-broadcast Spring Festival Gala, humanoid robots pulled off backflips and tightly synchronized choreography, a sharp contrast with last year’s more awkward demos. Analysts attribute the progress to better batteries, motors, and sensors—many riding the same supply chains that scaled up for electric vehicles—plus more capable AI control. One leading firm, Unitree, advertises a base price around $13,500 for its G1 model. Estimates cited in recent coverage put the global humanoid market in 2025 at roughly $2.5 billion, with China accounting for about half, and shipment counts rising sharply year over year. But there are caveats worth keeping in view: a choreographed performance doesn’t guarantee robust real-world perception and safe autonomy. Critics also flag data-collection and privacy risks, job disruption, and the possibility of an investment bubble. Still, the pace is real—and it’s increasingly clear that the question isn’t whether humanoids will show up in workplaces, but where, when, and under what rules.

To international justice: judges at the International Criminal Court in The Hague have opened a four-day confirmation of charges hearing for former Philippine President Rodrigo Duterte. This stage is not a verdict. The court is deciding whether there are substantial grounds to believe Duterte committed alleged crimes against humanity—specifically murder and attempted murder—linked to killings during the Philippines’ “war on drugs.” The alleged period spans from November 2011 to March 2019, covering both his time as mayor of Davao City and later as president. Prosecutors describe multiple sets of alleged crimes, including killings tied to the so-called Davao Death Squad and operations during his presidency. Duterte is currently detained at the ICC facility in Scheveningen. His defense is expected to challenge the prosecution’s theory and evidence, while legal representatives for 539 victims are also participating. The judges are expected to issue a written decision within 60 days after the hearing ends—confirming some or all charges and sending the case to trial, rejecting the charges, or asking for more evidence or amendments.

Now to diplomacy and unrest centered on Iran. Another round of Iran–US nuclear talks is expected in Geneva this week, with Iranian foreign minister Abbas Araghchi saying negotiators would likely meet on Thursday to try for what he called a “fast deal.” The reported opening here is Tehran signaling it may be willing to reduce its stockpile of highly enriched uranium and provide assurances it’s not pursuing a weapon—potentially through stricter verification. Iran’s position, as described, is to keep enrichment rights for peaceful purposes under tougher IAEA oversight, dilute the highly enriched stockpile, and allow access to bombed sites in exchange for sanctions relief. At the same time, the backdrop is tense: the US has redeployed significant military assets to the region, and Araghchi warned Iran would defend itself if attacked. Inside Iran, student protests reportedly continued for a second day at universities in Tehran and Mashhad, with contested casualty numbers from earlier unrest and Iran refusing entry to a UN-led fact-finding mission. It’s a reminder that any diplomatic track is running alongside intense domestic pressure and a charged security environment.

Finally, a look at the war’s long tail—and the markets trying to price uncertainty in real time. On demographics, four years after Russia’s full-scale invasion of Ukraine began on February 24th, 2022, fertility rates in both countries are sliding further. U.N. data puts Ukraine’s total fertility rate at about 1.00 in 2025, down from 1.22 in 2021, with Ukraine’s first lady citing even lower estimates in the 0.8 to 0.9 range. Russia’s rate has also declined, with 2024 births the lowest since 1999. Analysts point to displacement, deaths, family separation, damaged infrastructure, and emigration—factors that don’t snap back quickly even if fighting stops. On markets, U.S. stock futures dipped as investors digested lingering trade-policy whiplash after the Supreme Court struck down most of President Trump’s sweeping tariffs late last week. Traders are now watching what comes next, after Trump signaled alternative import taxes via executive action and Commerce Department investigations. In company moves, Novo Nordisk shares slid in premarket trading after weight-loss drug trial results disappointed compared with Eli Lilly, while Domino’s rose on strong same-store sales and an upbeat 2026 outlook. Bitcoin fell sharply, briefly dipping below $65,000, as risk appetite cooled and regulatory worries resurfaced. Gold jumped, silver surged, and oil edged higher—classic signs of markets juggling growth, policy uncertainty, and hedges all at once.